Pyramid Analytics and Smollan forge international partnership
22.8.2023 16:06:00 EEST | Business Wire | Press release
Global retail specialists Smollan have formalised an international reseller and implementation partnership agreement with next-generation decision and business intelligence (BI) software provider Pyramid Analytics. The agreement will see Smollan, via its data and technology business, DataOrbis, expanding its current service offering to include the ability to both sell Pyramid Analytics licenses and implement Pyramid Analytics software.
“Our clients operate in incredibly competitive industries, where the ability to make the best decision, quickly is the key to strong performance. Our hunt for a BI solution that delivers superior functionality, excellent value, and next-generation capability led us to Pyramid Analytics. We migrated the majority of our DataOrbis solutions onto their software last year, and already our clients are noticing a step-change in how we can help them capitalise on the explosive amount of data they have at their fingertips,” said James Collett, Smollan’s Chief Executive: Data & Technology.
The Pyramid Analytics partnership also provides DataOrbis with a growth opportunity geared at expanding DataOrbis’ services and footprint into verticals outside of the fast-moving consumer goods (FMCG) space where they have traditionally played. This is further supported by DataOrbis and Smollan’s global footprint, which includes operations in all major gateways.
“DataOrbis has an excellent understanding of what it takes to implement a successful data strategy across an organisation, regardless of industry. We are incredibly excited to be partnering with them internationally. By leveraging their global presence throughout their client and partner networks, I believe DataOrbis, together with Pyramid Analytics, can streamline and optimise their data analytics ecosystems to prepare them for what’s next. We are thrilled to have them on board,” said Omri Kohl, Pyramid Analytics CEO.
The Pyramid Platform consistently receives top ratings among leading analyst firms that evaluate business intelligence and analytics technologies. Most recently, Pyramid earned top rankings from Gartner in the 2023 Critical Capabilities for Analytics and Business Intelligence Platforms report, including #1 for Business Analyst Use Case, #1 for Augmented Consumer Use Case, #2 for Data Scientist Use Case, and #4 for Analytics Developer Use Case.
The Pyramid Platform consolidates data preparation, business analytics, and data science into a single, integrated, self-service platform that can be accessed by all levels of data users.
“The time it takes for a decision-maker to access data can make or break a company’s competitive advantage. Pyramid Analytics reduces the amount of time it takes users across the organisation to easily find the information they need without having to request it from IT. It’s a win-win for both users and overly stretched IT departments,” said Kohl.
Implementation is key to success
As the need to unlock the power of data has accelerated, businesses are realising the benefit of having one enterprise BI platform across the organisation, ensuring a single source of truth that can be safely, securely, and ethically managed. As an early adopter, DataOrbis has invested in creating and upskilling several Pyramid Analytics’ implementation teams working out of South Africa, India, and Slovenia to assist clients in creating and implementing their own unique global views. These teams, with over 50 certified Pyramid Analytics specialists, include senior resources with expertise across industries and geographies.
“The choice of BI platform is one part of the insights puzzle. The skill and time needed to implement the software is the next piece. In our experience, most companies don’t have these two vital resources readily available. By partnering with DataOrbis we can ensure the Pyramid Analytics software is expertly implemented and used to its fullest potential—all based on global best-practises. I am excited by the opportunities the Pyramid Analytics partnership will unlock for us and our clients,” said Collett.
ABOUT
Pyramid Analytics
Pyramid Analytics is the next generation of business analytics. The award-winning Pyramid Decision Intelligence Platform empowers people with augmented, automated, and collaborative insights that simplify and guide the use of data in decision-making. Critically, the Pyramid Analytics Platform operates directly on any data, enabling governed self-service for any person, and meeting analytical needs in a no-code environment without data extraction. It combines data prep, business analytics, and data science into one frictionless platform to empower anyone with intelligent decision-making. This enables a strategic, enterprise-wide approach to business intelligence and analytics, from the simple to the sophisticated. Schedule a demo. To find out more about Pyramid Analytics contact pr@pyramidanalytics.com.
Smollan
Founded in 1931, Smollan is a global commerce business, delivering growth for retailers and brand owners across five continents. Influencing what, when, where and shoppers browse and buy across multiple touchpoints, through Sales & Merchandising, Activation & Experience, Data & Technology and Digital Commerce. Internationally recognised for our exceptional human platform of over 75 000 people and our sophisticated systems, we drive sales and create brilliant shopper experiences for some of the world’s most loved brands. We are a global business that helps retailers and brands win at the point of purchase. Contact us at www.smollan.com.
DataOrbis
A leading data and technology company, DataOrbis uses its SMART ecosystem of services, solutions and technology to expertly help companies transform into businesses driven by data. With over 50 blue-chip clients, DataOrbis currently processes over 300 sources of data across 60+ countries in multiple languages. In 2020, DataOrbis joined forces with global retail specialist Smollan, increasing its ability to scale, expand and network globally.
DataOrbis is headquartered in South Africa with offices and partners across the globe. To find out more about DataOrbis contact us here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230822485425/en/
Contact information
Pete Vomocil
Senior Vice President, Global Marketing, Pyramid Analytics
E-Mail: pr@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release
Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom